Aurobindo Pharma receives USFDA's nod for Ramipril Capsules

10 Jun 2011 Evaluate

Aurobindo Pharma has received final approval from the US Food and Drug Administration (USFDA) to manufacture and market Ramipril Capsules USP 1.25mg, 2.5mg, 5mg and 10mg. The product has a market size of approximately $95 million for the twelve months ending September 2010 according to IMS.

Ramipril Capsules USP 1.25mg, 2.5mg, 5mg and 10mg is the generic equivalent to the reference listed drug Altace Capsules 1.25mg, 2.5mg, 5mg and 10mg of King Pharmaceuticals. Under the Cardiovascular (CVS) therapeutic segment Ramipril Capsules are indicated for the treatment of hypertension. Aurobindo now has a total of 138 ANDA approvals (108 Final approvals and 30 tentative approvals) from USFDA.

Aurobindo Pharma manufactures generic pharmaceuticals and active pharmaceutical ingredients. The company’s robust product portfolio is spread over 6 major therapeutic/product areas encompassing Antibiotics, Anti-Retrovirals, CVS, CNS, Gastroenterological, and Anti-Allergics, supported by an outstanding R&D set-up. The Company is marketing these products globally, in over 125 countries.

Aurobindo Pharma Share Price

1220.20 -27.70 (-2.22%)
21-Nov-2024 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1777.65
Dr. Reddys Lab 1194.55
Cipla 1465.65
Lupin 2043.30
Zydus Lifesciences 944.25
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.